Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Tibet Rhodiola Pharmaceutical Holding Co
Operating Expenses
Tibet Rhodiola Pharmaceutical Holding Co
Operating Expenses Peer Comparison
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
Operating Expenses
-¥1.8B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-21%
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Operating Expenses
-¥26.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-15%
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Operating Expenses
-¥22.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-12%
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Operating Expenses
-¥7.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-17%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Operating Expenses
-¥1.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-15%
|
Huadong Medicine Co Ltd
SZSE:000963
|
Operating Expenses
-¥8.9B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-15%
|
See Also
What is Tibet Rhodiola Pharmaceutical Holding Co's Operating Expenses?
Operating Expenses
-1.8B
CNY
Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Operating Expenses amounts to -1.8B CNY.
What is Tibet Rhodiola Pharmaceutical Holding Co's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-21%
Over the last year, the Operating Expenses growth was -6%. The average annual Operating Expenses growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been -34% over the past three years , -28% over the past five years , and -21% over the past ten years .